Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Total Current Liabilities
All obligations due within one year.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 263.9% from a year ago
Total current liabilities stood at $5.24M at the end of Q1 FY2026, up 263.9% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at +180.9% a year.
Context
- Total current liabilities amounted to 49.8% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +263.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.82M USD
- Year-over-year change
- +273.4%
- 4-year CAGR
- +97.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.82M | +273.4% |
| FY2024 | 2024-12-31 | 1.56M | +429.8% |
| FY2023 | 2023-12-31 | 294.41K | +12.0% |
| FY2022 | 2022-12-31 | 262.91K | -31.7% |
| FY2021 | 2021-12-31 | 385.17K | — |
Total Current Liabilities vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +263.9% is the highest of 9, against a peer median of -7.8%.
- Total current liabilities amounts to 49.8% of total assets for GLSI, versus a peer median of 15.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $249.24M USD | +19.7% | +19.6% | 133.7% | |
| Mar 2026 | $10.54M USD | +13.2% | +99.5% | 11.0% | |
| Mar 2026 | $10.24M USD | -22.4% | +7.6% | 3.8% | |
| Mar 2026 | $9.57M USD | -9.6% | +0.7% | 7.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M USD | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $6.07M USD | +26.9% | +27.3% | 20.4% | |
| Mar 2026 | $6.05M USD | -44.7% | +21.3% | 16.7% | |
| Mar 2026 | CA$5.42M CAD | -6.0% | +28.5% | 66.5% | |
| Mar 2026 | $5.24M USD | +263.9% | +180.9% | 49.8% | |
| Peer median (excluding GLSI) | — | -7.8% | +24.3% | 15.4% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.